David SansCAR T Cells: A Novel Approach to Cancer TreatmentDavid Sans suggested that, The development of CAR T cells (chimeric antigen receptor) technology provides a novel approach to cancer…Mar 23, 2022Mar 23, 2022
David SansDavid Sans Discusses Axonal Transport and How It Could Help Patients with Alzheimer’sNEW YORK, NY / ACCESSWIRE / October 1, 2021 / is a noted investor and a philanthropist in the healthcare industry. He looks at how axonal…Oct 1, 2021Oct 1, 2021
David SansXORTX Appoints Dr. David Sans in New York as Director Corporate Development | BioSpaceCALGARY, Alberta, Aug. 07, 2020 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc.. (“XORTX” or the “Company”) (CSE: XRX) (OTCQB: XRTXF), a…Sep 30, 2021Sep 30, 2021
David SansMerriman Capital Adds Health Care Investment Banker David Sans, Ph.D.SAN FRANCISCO, Sept. 5, 2012 /PRNewswire/ — Merriman Capital, Inc., a wholly owned subsidiary of Merriman Holdings, Inc. (OTCQX: MERR)…Sep 30, 2021Sep 30, 2021
David SansGabriel Yariv, Executive Director of Cannabics Pharmaceuticals and Dr.TEL AVIV, Israel and BETHESDA, Md., Sept. 22, 2021 /PRNewswire/ — Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the…Sep 22, 2021Sep 22, 2021
David SansGabriel Yariv, Executive Director of Cannabics Pharmaceuticals and Dr.TEL AVIV, Israel and BETHESDA, Md., Sept. 22, 2021 /PRNewswire/ — Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the…Sep 22, 2021Sep 22, 2021
David SansGabriel Yariv, Executive Director of Cannabics Pharmaceuticals and Dr.TEL AVIV, Israel and BETHESDA, Md., Sept. 22, 2021 /PRNewswire/ — Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the…Sep 22, 2021Sep 22, 2021
David SansXORTX Appoints Dr. David Sans in New York as Director Corporate DevelopmentCALGARY, Alberta, Aug. 07, 2020 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX) (OTCQB: XRTXF), a…Aug 7, 2020Aug 7, 2020
